1. Jeuveau


Active ingredient: prabotulinumtoxinA-xfvs
Disease: frown lines
Peak sales estimate: $250 million in 2025
Approved: Feb. 1, 2019
Company: Evolus

The scoop: Allergan’s Botox has had some competition in the frown lines department, but none of it had been all that serious—until Evolus’ Jeuveau came along. Unlike previous competitors from Galderma and Merz, “this is the first toxin that is really similar to Allergan’s Botox, a claim which is supported by a head-to-head study,” SVB Leerink analyst Marc Goodman wrote to clients in November. Speaking of similar, the two products also bear identical molecular weights, a factor analysts predicted might make Jeuveau easier to sub in for the Allergan standby. And Evolus’ C-suite knows what it’s doing: Its chief medical officer, chief marketing officer and CEO/CFO all have experience in the market. — Carly Helfand

Suggested Articles

With case counts surging and top officials infected, the U.K. is joining the testing for Gilead Sciences' much-hyped antiviral candidate remdesivir.

By redeploying staff, the FDA thinks it can respond to COVID-19-related requests and review protocols within 24 hours of receipt.

The partners leveraged their proximity to the initial outbreak and experience with SARS and MERS to build up a library of neutralizing antibodies.